View Mode:
JS
Real-Time Alerts
All Alerts
Sort by:
High Priority
FDA issues new guidance for immuno-oncology trial endpoints
This guidance may impact multiple ongoing trials across several companies.
Merck
BMS
Roche
AstraZeneca
1h ago
•
Regulatory
Pfizer announces positive Phase 3 results for PF-06939926
Gene therapy for Duchenne muscular dystrophy met primary endpoint.
2h ago
•
Clinical Trial
•
Medium Priority
Novartis receives FDA approval for Kesimpta in RMS
First self-administered, targeted B-cell therapy for relapsing multiple sclerosis.
5h ago
•
Regulatory
•
Medium Priority
Merck's KEYTRUDA meets primary endpoint in KEYNOTE-598
Trial evaluating KEYTRUDA in combination with ipilimumab in metastatic non-small cell lung cancer.
8h ago
•
Clinical Trial
•
Medium Priority
AstraZeneca presents new data for TAGRISSO at WCLC
Updated overall survival data from the ADAURA Phase III trial.
1d ago
•
Conference
•
Low Priority
EMA approves first biosimilar for Humira in Europe
Approval may impact market dynamics for autoimmune treatments.
AbbVie
Pfizer
Amgen
2d ago
•
Regulatory
•
Medium Priority
Showing 1 to 5 of 42 alerts
© 2025 CI Agent. All rights reserved.